Quince Therapeutics (QNCX) Competitors $1.22 +0.09 (+8.00%) As of 03:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock QNCX vs. GOSS, ANNX, HURA, DBVT, PRME, NGNE, GNFT, ELDN, VYGR, and TVGNShould you be buying Quince Therapeutics stock or one of its competitors? The main competitors of Quince Therapeutics include Gossamer Bio (GOSS), Annexon (ANNX), TuHURA Biosciences (HURA), DBV Technologies (DBVT), Prime Medicine (PRME), Neurogene (NGNE), Genfit (GNFT), Eledon Pharmaceuticals (ELDN), Voyager Therapeutics (VYGR), and Tevogen Bio (TVGN). These companies are all part of the "pharmaceutical products" industry. Quince Therapeutics vs. Gossamer Bio Annexon TuHURA Biosciences DBV Technologies Prime Medicine Neurogene Genfit Eledon Pharmaceuticals Voyager Therapeutics Tevogen Bio Quince Therapeutics (NASDAQ:QNCX) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends. Do insiders and institutionals hold more shares of QNCX or GOSS? 30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 16.8% of Quince Therapeutics shares are owned by insiders. Comparatively, 5.0% of Gossamer Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility & risk, QNCX or GOSS? Quince Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500. Does the media refer more to QNCX or GOSS? In the previous week, Gossamer Bio had 4 more articles in the media than Quince Therapeutics. MarketBeat recorded 4 mentions for Gossamer Bio and 0 mentions for Quince Therapeutics. Gossamer Bio's average media sentiment score of 0.89 beat Quince Therapeutics' score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the news media. Company Overall Sentiment Quince Therapeutics Neutral Gossamer Bio Positive Is QNCX or GOSS more profitable? Quince Therapeutics' return on equity of -53.27% beat Gossamer Bio's return on equity.Company Net Margins Return on Equity Return on Assets Quince TherapeuticsN/A -53.27% -22.73% Gossamer Bio N/A -127.28%-22.12% Which has higher valuation & earnings, QNCX or GOSS? Quince Therapeutics has higher earnings, but lower revenue than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuince TherapeuticsN/AN/A-$31.39M-$1.31-0.93Gossamer Bio$114.70M1.91-$179.82M-$0.26-3.71 Do analysts rate QNCX or GOSS? Quince Therapeutics presently has a consensus price target of $8.00, suggesting a potential upside of 558.44%. Gossamer Bio has a consensus price target of $7.50, suggesting a potential upside of 678.01%. Given Gossamer Bio's higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Quince Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer QNCX or GOSS? Gossamer Bio received 146 more outperform votes than Quince Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Quince Therapeutics an outperform vote while only 66.81% of users gave Gossamer Bio an outperform vote. CompanyUnderperformOutperformQuince TherapeuticsOutperform Votes9100.00% Underperform VotesNo VotesGossamer BioOutperform Votes15566.81% Underperform Votes7733.19% SummaryGossamer Bio beats Quince Therapeutics on 9 of the 17 factors compared between the two stocks. Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QNCX vs. The Competition Export to ExcelMetricQuince TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.52M$2.91B$5.43B$7.80BDividend YieldN/A1.91%5.44%4.31%P/E Ratio-0.9829.2322.2418.35Price / SalesN/A480.06389.36100.72Price / CashN/A168.6838.2034.62Price / Book0.613.036.654.17Net Income-$31.39M-$72.17M$3.21B$247.71M7 Day Performance22.67%9.41%5.49%6.17%1 Month Performance-11.31%-6.24%-4.63%-3.37%1 Year Performance17.96%-19.55%17.67%5.25% Quince Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QNCXQuince Therapeutics2.0112 of 5 stars$1.22+8.0%$8.00+558.4%+6.1%$53.52MN/A-0.9860Gap UpGOSSGossamer Bio3.7682 of 5 stars$0.81-3.5%$7.50+822.5%+38.2%$184.73M$114.70M-2.54180ANNXAnnexon2.6633 of 5 stars$1.68+15.1%$18.67+1,011.1%-57.1%$184.31MN/A-1.6060Positive NewsGap UpHURATuHURA BiosciencesN/A$4.20+1.2%$12.67+201.6%N/A$183.46MN/A0.00N/AGap DownDBVTDBV Technologies3.1094 of 5 stars$8.91+11.7%$22.50+152.5%+33.8%$183.30M$15.73M-1.9880Analyst ForecastPositive NewsGap DownPRMEPrime Medicine2.776 of 5 stars$1.39+12.1%$13.38+862.2%-62.8%$182.31M$2.98M-0.68234High Trading VolumeNGNENeurogene2.2373 of 5 stars$12.02+4.6%$47.20+292.7%-49.2%$179.46M$925,000.00-2.8190GNFTGenfit1.1107 of 5 stars$3.57+1.7%$13.00+264.1%+6.5%$178.49M$76.06M0.00120News CoverageGap UpELDNEledon Pharmaceuticals2.0445 of 5 stars$2.98-0.3%$12.50+319.5%+70.6%$178.45MN/A-1.4810VYGRVoyager Therapeutics4.5355 of 5 stars$3.21+1.6%$13.97+335.1%-53.4%$177.21M$80.00M4.52100TVGNTevogen Bio3.7114 of 5 stars$0.93-4.8%$7.10+661.6%-32.7%$171.44MN/A0.003 Related Companies and Tools Related Companies Gossamer Bio Alternatives Annexon Alternatives TuHURA Biosciences Alternatives DBV Technologies Alternatives Prime Medicine Alternatives Neurogene Alternatives Genfit Alternatives Eledon Pharmaceuticals Alternatives Voyager Therapeutics Alternatives Tevogen Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QNCX) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
